Takeda Pharmaceutical Co Ltd (TAK)
13.12
-0.05
(-0.38%)
USD |
NYSE |
Apr 30, 13:08
Takeda Pharmaceutical Enterprise Value: 72.15B for April 29, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 29, 2024 | 72.15B |
| April 26, 2024 | 71.71B |
| April 25, 2024 | 71.84B |
| April 24, 2024 | 72.34B |
| April 23, 2024 | 72.81B |
| April 22, 2024 | 72.75B |
| April 19, 2024 | 72.37B |
| April 18, 2024 | 72.12B |
| April 17, 2024 | 72.09B |
| April 16, 2024 | 72.34B |
| April 15, 2024 | 72.18B |
| April 12, 2024 | 72.78B |
| April 11, 2024 | 73.44B |
| April 10, 2024 | 73.41B |
| April 09, 2024 | 73.66B |
| April 08, 2024 | 73.72B |
| April 05, 2024 | 73.56B |
| April 04, 2024 | 73.13B |
| April 03, 2024 | 73.28B |
| April 02, 2024 | 73.35B |
| April 01, 2024 | 73.72B |
| March 28, 2024 | 74.41B |
| March 27, 2024 | 75.35B |
| March 26, 2024 | 75.98B |
| March 25, 2024 | 75.23B |
| Date | Value |
|---|---|
| March 22, 2024 | 76.04B |
| March 21, 2024 | 75.89B |
| March 20, 2024 | 76.48B |
| March 19, 2024 | 76.04B |
| March 18, 2024 | 76.51B |
| March 15, 2024 | 76.23B |
| March 14, 2024 | 75.82B |
| March 13, 2024 | 76.08B |
| March 12, 2024 | 75.92B |
| March 11, 2024 | 76.55B |
| March 08, 2024 | 77.17B |
| March 07, 2024 | 77.46B |
| March 06, 2024 | 76.92B |
| March 05, 2024 | 76.01B |
| March 04, 2024 | 76.26B |
| March 01, 2024 | 76.51B |
| February 29, 2024 | 76.61B |
| February 28, 2024 | 76.80B |
| February 27, 2024 | 77.39B |
| February 26, 2024 | 77.30B |
| February 23, 2024 | 76.70B |
| February 22, 2024 | 76.77B |
| February 21, 2024 | 77.08B |
| February 20, 2024 | 77.33B |
| February 16, 2024 | 76.70B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
65.66B
Minimum
Oct 19 2022
107.09B
Maximum
Nov 19 2019
85.32B
Average
80.89B
Median
Sep 14 2023
Enterprise Value Benchmarks
| Hoya Corp | 38.49B |
| Astellas Pharma Inc | 21.42B |
| Nxera Pharma Co Ltd | 972.08M |
| PeptiDream Inc | 1.250B |
| Stemcell Holdings Inc | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 716.00M |
| Revenue (Quarterly) | 7.526B |
| Total Expenses (Quarterly) | 7.076B |
| EPS Diluted (Quarterly) | 0.2265 |
| Gross Profit Margin (Quarterly) | 65.85% |
| Profit Margin (Quarterly) | 9.51% |
| Earnings Yield | 3.06% |
| Operating Earnings Yield | 6.00% |
| Normalized Earnings Yield | 3.060 |